Volume : 09, Issue : 05, May – 2022
Title:
36.RECENT TREATMENT ON TUBERCULOSIS: A SYSTEMIC REVIEW
Authors :
Dr. Anita Chowbey*
Abstract :
Tuberculosis (TB) is an infectious illness spread through the air that poses a global health issue. TB was the largest cause of death due to a single infectious agent worldwide until the introduction of COVID-19, which is caused by the SARS-Cov-2 virus. It’s caused by Mycobacterium, a bacterial genus with a diverse range of hosts, susceptibilities, and infection path physiology. The conflict is fought on the basis of genuine knowledge, with mankind armed with past experience and modern medicine to defeat this ancient foe in all of its forms. This collection of review articles is an honest attempt to raise TB awareness.
Key words: Tuberculosis, Treatment, Review
Cite This Article:
Please cite this article in press Anita Chowbey et al, Recent Treatment On Tuberculosis: A Systemic Review., Indo Am. J. P. Sci, 2022; 09(5).,
Number of Downloads : 10
References:
1. World Health Organization. Global Tuberculosis Report; 2021.
2. Quinn PJ, Markey BK, Leonard FC, Hartigan P, Fanning S, Fitzpatrick ES. Veterinary Microbiology and Microbial Disease. 2nd edition. Oxford: Blackwell Science Ltd; 2011.
3. Morse SS, Mazet JA, Woolhouse M, Parrish R, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. Lancet. 2012;380(9857):1956-1965.
4. World Health Organization. Global Tuberculosis Report; 2020.
5. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127-2135. Global Control of Tuberculosis: Current Status and Future Prospects 5
6. World Health Organization. WHO Tuberculosis Programme: Framework for Effective Tuberculosis Control; 1994.
7. Raviglione MC, Uplekar MW. WHO’s new Stop TB Strategy. Lancet. 2006;367(9514):952-955.
8. Alagna R, Besozzi G, Codecasa LR, Gori A, Migliori GB, Raviglione M, et al. Celebrating World Tuberculosis Day at the time of COVID-19. Eur Respir J. 2020;55(4):2000650.
9. Schrager LK, Vekemens J, Drager N, Lewinsohn DM, Olesen OF. The status of tuberculosis vaccine development. Lancet Infect Dis. 2020;20(3):e28-e37.
10. World Health Organization. WHO consolidated guidelines on tuberculosis, module 4: treatment – drug-resistant tuberculosis treatment; 2020.
11. Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M. Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives. Eur Respir J. 2017;50(5):1701632.
12. Cadmus S, Akinseye VO, van Soolingen D. Mycobacterium bovis in humans and M. tuberculosis in animals in Nigeria: an overview from 1975-2014. Int J Tuberc Lung Dis. 2019;23(11):1162-1170.
13. Kleeberg H. Human tuberculosis of bovine origin in relation to public health. Rev Sci Tech Off Int Epiz. 1984;3(1):11-32.
14. WHO, OIE, FAO, UNION. Roadmpa for Zoonotic Tuberculosis [accessed 2021 Aug 2]. Available from: http://apps.who.int/iris/ bitstream/10665/259229/1/9789241513043-eng.pdf?ua=1.
15. Luciano SA, Roess A. Human zoonotic tuberculosis and livestock exposure in low- and middle-income countries: a systematic review identifying challenges in laboratory diagnosis. Zoonoses Public Health. 2020;67(2):97-111.
16. Olea-Popelka F, Muwonge A, Perera A, Dean AS, Mumford E, Erlacher-Vindel E, et al. Zoonotic tuberculosis in human beings caused by Mycobacterium bovis-a call for action. Lancet Infect Dis. 2017;17(1):e21-e25.
17. Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 2020;28:100603.
18. McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021;25(6):436-446.
19. WHO/CDS/TB/2003.313. Treatments of tuberculosis: guidelines for national programmes; third edition revision approved by STAG, June 2004 and TDR meeting on 4FDCs 15–17 Aug 2001 [online resource]. http:// www.who.int/tb/en/ [Accessed: 20 November 2005
20. Sirgel FA, Fourie FA, Donald PR, et al. The early bacterial activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172:128–135.
21. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother 2005; 55:430–435. This is a very good review about new strategies in antitubercular inhaled therapy.
22. Long R, Jones R, Talbot J, et al. Inhaled nitric oxide treatment of patients with pulmonary tuberculosis evidence by positive sputum smears. Antimicrob Agents Chemother 2005; 49:1209–1212.
23. Pandey R, Khuller GK. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 2005; 85:227–234.
24. Andrews JR, Hatherill M, Mahomed H, et al. The dynamics of QuantiFERON-TB Gold In-Tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 2015; 191: 584–91.
25. Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol 2017; 8: 1134.
26. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014 ; 58: 470–80.
27. Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M tuberculosis infection with H4:IC31 vaccine or BCG revaccination. N Engl J Med 2018; 379: 138–49.
28. Spencer CT, Abate G, Blazevic A, Hoft DF. Only a subset of phosphoantigen-responsive γ9δ2 T cells mediate protective tuberculosis immunity. J Immunol 2008; 181: 4471–84.
29. Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 2011; 17: 189–94.
30. Achkar JM, Chan J, Casadevall A. B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev 2015; 264: 167–81.
31. Tkachuk AP, Gushchin VA, Potapov VD, Demidenko AV, Lunin VG, Gintsburg AL. Multi-subunit BCG booster vaccine GamTBvac: assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS One 2017; 12: e0176784.